TNFRSF9 and neoplasm: Further, it has been reported that agonistic activation of 4-1BB induced CD4+ and CD8+ T cell activation, and prevented their activation-induced death, making these agonist antibodies an ideal therapeutic candidate to enhance anti-tumor immunity [29, 30].